• American Medical Directors Association (AMDA). Parkinson's disease in the long-term care setting. Columbia (MD): American Medical Directors Association (AMDA); 2002. 34 p. [16 references]

This is the current release of the guideline.

According to the guideline developer, this guideline was reviewed by the original Steering Committee and is still considered to be current as of Jan 2007. This review involved new literature searches of electronic databases followed by expert committee review of new evidence that has emerged since the original publication date.

The guideline was developed by an interdisciplinary work group using a process that combined evidence- and consensus-based thinking.

• American Medical Directors Association (AMDA). Parkinson's disease in the long-term care setting. Columbia (MD): American Medical Directors Association (AMDA); 2002. 34 p. [16 references]

Not applicable: Guideline was not adapted from another source.

2002 (reviewed 2007)

American Medical Directors Association - Professional Association

Organizational participants included:

• American Association of Homes and Services for the Aging
• American College of Health Care Administrators
• American Health Care Association
• American Society of Consultant Pharmacists
• National Association of Directors of Nursing Administration in Long-Term Care
• National Association of Geriatric Nursing Assistants
• National Conference of Gerontological Nurse Practitioners

Corporate supporters of this guideline include Aventis Pharmaceuticals, Forest Laboratories, Inc, GlaxoSmithKline, Janssen Eldercare, LifeScan, Novartis Pharmaceuticals, Pfizer, Inc, Pharmacia Corporation, and Organon, Inc.

Steering Committee

Larry W. Lawhorne, MD, CMD, Project Chair

Steven Levenson, MD, CMD, Chair Clinical Practice Committee

Committee Members: Charles Cefalu, MD, MS, Chair; Lisa Cantrell, RNC, Co-Chair; Sandra Brownstein, Pharm D. FASCP, CGP; Annette Carron, D.O.; Linda L. Cook, RNC, LSW; Vincent DeLuzio, Rec. Therapist; Danielle Dodman, MS,CCC-SLP; Dianne Fiore, OT,R.; Ira Leroi, MD; Jill Marjama-Lyons, MD; Lu Anne Reed, BSN, RNC, CRRN; Cynthia Ross, CNA; Anne Skalmoski, PT; Teresa Tempkin, RNC, MSN, ANP

Not stated

This is the current release of the guideline.

According to the guideline developer, this guideline was reviewed by the original Steering Committee and is still considered to be current as of Jan 2007. This review involved new literature searches of electronic databases followed by expert committee review of new evidence that has emerged since the original publication date.

None available

This NGC summary was completed by ECRI on September 3, 2003. The information was verified by the guideline developer on April 8, 2004. This summary was updated by ECRI on January 18, 2006, following the U.S. Food and Drug Administration advisory on Clozaril (clozapine). This summary was updated by ECRI on May 31, 2006 following the U.S. Food and Drug Administration advisory on Paxil (paroxetine hydrochloride). This summary was updated by ECRI on November 22, 2006, following the FDA advisory on Effexor (venlafaxine HCl). This summary was updated by ECRI Institute on April 17, 2007 following the withdrawal from the market of Permax (pergolide). This summary was updated by ECRI Institute on November 2, 2007, following the U.S. Food and Drug Administration advisory on Antidepressant drugs. This summary was updated by ECRI Institute on July 25, 2008, following the U.S. Food and Drug Administration advisory on Antipsychotics.

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. For more information, please contact the American Medical Directors Association (AMDA) at (800) 876-2632.